GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its primary manufacturing facility for oligonucleotide and peptide production at Zhenjiang, Jiangsu, China. The expansion builds on GenScript's reputation for supporting scientists worldwide by offering high-quality oligo and peptides for 20 years.

The expanded oligonucleotide synthesis capability offers qPCR oligos, NGS oligos, RNA oligos, DNA oligos and more to support a wide range of applications — from molecular diagnostics, RNAi, to genome editing. Equipped with high-throughput, large-scale synthesizers, HPLC+ and PAGE+ purification processes for stringent cross-contamination control, as well as ISO 13485 certification, GenScript provides up to 200nt DNA and 180nt RNA oligonucleotides from ug to kilogram level with up to 95% purity to meet diverse application needs.

Similarly, using its proprietary, microwave-assisted PepPower™ peptide synthesis platform, GenScript has been offering high-quality custom peptides and peptide libraries with 100% guaranteed quantity at industry-leading speed—as fast as 5 days—to help expedite research projects. With this expansion, four new dynamic axial compression columns have been added to large-scale peptides, achieving an average monthly production capacity of more than 5kg, and 32sq.ft. of freeze dryers to support the mass freeze-drying process. Newly expanded production lines also enable GenScript to deliver up to 30,000 peptides per month and offer kilogram-level batch production. GenScript is fully committed to supporting peptide researchers in areas from peptide drug and vaccine development to functional screening and neoantigen discovery.

"GenScript's new site in Zhenjiang is poised to offer unparalleled support and address the increasing demand for oligonucleotide and peptide synthesis — serving the areas such as molecular diagnostics, RNA and peptide drug development, vaccine development, gene editing by providing faster, more reliable, and more cost-effective solutions via our cutting-edge platforms at different scales," said Dr. Ray Chen, president of the Life Science Group at GenScript.